Harnessing the power of radiopharmaceuticals

Alpha-9 is a leading, clinical stage radiopharmaceutical company, advancing a distinctive portfolio of molecules. Using targeted, bespoke molecules, we treat cancer cells with unparalleled precision. At Alpha-9, we’re not just advancing cancer care; we’re illuminating new possibilities in precision medicine.

Learn More

Science of radiopharmaceuticals

Radiopharmaceuticals provide transformational outcomes for patients and offer distinct advantages that speed up the process of moving from bench to bedside.

Our Science

Alpha-9’s approach

Alpha-9 employs a bespoke, iterative process to optimize each part of the molecule – binder, linker, chelator, and radioisotope. The Alpha-9 approach is supported by state-of-the-art infrastructure and in-house formulation expertise.

Our Approach

Our team

Alpha-9’s leadership team has decades of expertise in oncology drug development. The company is backed by top-tier investors and founders with extensive experience in radiopharmaceuticals.

Meet the Team

News & Events

Recent press releases

October 23, 2024

Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals

BOSTON, Mass. and VANCOUVER, British Columbia, October 23, 2024 – Alpha-9 Oncology Inc. (Alpha-9 or the Company), a clinical stage company developing...

October 15, 2024

Alpha-9 Oncology Appoints Jean-Jacques Bienaimé and Dr. Steven Stein to its Board of Directors

BOSTON, Mass. and VANCOUVER, British Columbia, October 15, 2024 – Alpha-9 Oncology (“Alpha-9” or the “Company”), a clinical stage company developing radiopharmaceuticals...

May 2, 2024

Alpha-9 Oncology Announces First Patient Dosed in Phase 1 Study of A9-3202 in Patients with Locally Advanced or Metastatic Melanoma

BOSTON, Mass. and VANCOUVER, British Columbia, May 2, 2024 — Alpha-9 Oncology (Alpha-9), a clinical stage company developing radiopharmaceuticals for the treatment of...